- Home
- CRGX vs STK Comparison
CRGX vs STK Comparison
Compare CRGX & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- STK
- Stock Information
- Founded
- CRGX 2021
- STK 2009
- Country
- CRGX United States
- STK United States
- Employees
- CRGX N/A
- STK N/A
- Industry
- CRGX
- STK Investment Managers
- Sector
- CRGX
- STK Finance
- Exchange
- CRGX Nasdaq
- STK Nasdaq
- Market Cap
- CRGX 815.7M
- STK 563.6M
- IPO Year
- CRGX 2023
- STK N/A
- Fundamental
- Price
- CRGX $21.70
- STK $33.46
- Analyst Decision
- CRGX Strong Buy
- STK
- Analyst Count
- CRGX 7
- STK 0
- Target Price
- CRGX $30.33
- STK N/A
- AVG Volume (30 Days)
- CRGX 416.1K
- STK 38.2K
- Earning Date
- CRGX 11-21-2024
- STK 01-01-0001
- Dividend Yield
- CRGX N/A
- STK 6.60%
- EPS Growth
- CRGX N/A
- STK N/A
- EPS
- CRGX N/A
- STK N/A
- Revenue
- CRGX N/A
- STK N/A
- Revenue This Year
- CRGX N/A
- STK N/A
- Revenue Next Year
- CRGX N/A
- STK N/A
- P/E Ratio
- CRGX N/A
- STK N/A
- Revenue Growth
- CRGX N/A
- STK N/A
- 52 Week Low
- CRGX $13.14
- STK $24.95
- 52 Week High
- CRGX $33.92
- STK $34.31
- Technical
- Relative Strength Index (RSI)
- CRGX 58.91
- STK 55.94
- Support Level
- CRGX $19.61
- STK $33.07
- Resistance Level
- CRGX $19.51
- STK $34.11
- Average True Range (ATR)
- CRGX 1.19
- STK 0.46
- MACD
- CRGX 0.36
- STK 0.00
- Stochastic Oscillator
- CRGX 73.67
- STK 58.09
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.